A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS

Summary

This is the first study of the safety of increasing dose levels of AEB1102 in patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. The study will also evaluate the amounts of AEB1102 in blood, the effects of AEB1102 on blood amino acid levels and the antitumor effects of AEB1102.

Timeline

Start

2016-08

Primary completion

2017-12

Completion

2017-12

Drugs

Indications